A prion protein epitope selective for the pathologically misfolded conformation

被引:213
作者
Paramithiotis, E
Pinard, M
Lawton, T
LaBoissiere, S
Leathers, VL
Zou, WQ
Estey, LA
Lamontagne, J
Lehto, MT
Kondejewski, LH
Francoeur, GP
Papadopoulos, M
Haghighat, A
Spatz, SJ
Head, M
Will, R
Ironside, J
O'Rourke, K
Tonelli, Q
Ledebur, HC
Chakrabartty, A
Cashman, NR
机构
[1] Caprion Pharmaceut Inc, St Laurent, PQ H4S 2C8, Canada
[2] IDEXX Labs Inc, Westbrook, ME 04092 USA
[3] Western Gen Hosp, Natl Creutzfeldt Jakob Dis Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland
[4] Washington State Univ, USDA ARS, ADRU, Pullman, WA 99164 USA
[5] Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada
[6] Univ Toronto, Ctr Res Neurodegenrat Dis, Toronto, ON M5S 3H2, Canada
[7] Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
基金
加拿大健康研究院;
关键词
D O I
10.1038/nm883
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Conformational conversion of proteins in disease is likely to be accompanied by molecular surface exposure of previously sequestered amino-acid side chains. We found that induction of beta-sheet structures in recombinant prion proteins is associated with increased solvent accessibility of tyrosine. Antibodies directed against the prion protein repeat motif, tyrosine-tyrosine-arginine, recognize the pathological isoform of the prion protein but not the normal cellular isoform, as assessed by immunoprecipitation, plate capture immunoassay and flow cytometry. Antibody binding to the pathological epitope is saturable and specific, and can be created in vitro by partial denaturation of normal brain prion protein. Conformation-selective exposure of Tyr-Tyr-Arg provides a probe for the distribution and structure of pathologically misfolded prion protein, and may lead to new diagnostics and therapeutics for prion diseases.
引用
收藏
页码:893 / 899
页数:7
相关论文
共 45 条
[1]   Prion research: the next frontiers [J].
Aguzzi, A ;
Weissmann, C .
NATURE, 1997, 389 (6653) :795-798
[2]   NEARLY UBIQUITOUS TISSUE DISTRIBUTION OF THE SCRAPIE AGENT PRECURSOR PROTEIN [J].
BENDHEIM, PE ;
BROWN, HR ;
RUDELLI, RD ;
SCALA, LJ ;
GOLLER, NL ;
WEN, GY ;
KASCSAK, RJ ;
CASHMAN, NR ;
BOLTON, DC .
NEUROLOGY, 1992, 42 (01) :149-156
[3]   IDENTIFICATION OF A PROTEIN THAT PURIFIES WITH THE SCRAPIE PRION [J].
BOLTON, DC ;
MCKINLEY, MP ;
PRUSINER, SB .
SCIENCE, 1982, 218 (4579) :1309-1311
[4]   CELLULAR ISOFORM OF THE SCRAPIE AGENT PROTEIN PARTICIPATES IN LYMPHOCYTE-ACTIVATION [J].
CASHMAN, NR ;
LOERTSCHER, R ;
NALBANTOGLU, J ;
SHAW, I ;
KASCSAK, RJ ;
BOLTON, DC ;
BENDHEIM, PE .
CELL, 1990, 61 (01) :185-192
[5]   Oxygen and acrylamide quenching of protein phosphorescence: correlation with protein dynamics [J].
Cioni, P .
BIOPHYSICAL CHEMISTRY, 2000, 87 (01) :15-24
[6]  
Coulthart MB, 2001, CAN MED ASSOC J, V165, P51
[7]   Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody [J].
Enari, M ;
Flechsig, E ;
Weissmann, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (16) :9295-9299
[8]   Binding of disease-associated prion protein to plasminogen [J].
Fischer, MB ;
Roeckl, C ;
Parizek, P ;
Schwarz, HP ;
Aguzzi, A .
NATURE, 2000, 408 (6811) :479-483
[9]  
GAJDUSEK DC, 1986, VIROLOGY, P1516
[10]   Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies [J].
Heppner, FL ;
Musahl, C ;
Arrighi, I ;
Klein, MA ;
Rülicke, T ;
Oesch, B ;
Zinkernagel, RM ;
Kalinke, U ;
Aguzzi, A .
SCIENCE, 2001, 294 (5540) :178-182